Top

Gut Pathogens

Published in:

Open Access 01-12-2019 | Escherichia Coli | Research

Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses

Authors: Radwa N. Morgan, Sarra E. Saleh, Hala A. Farrag, Mohammad M. Aboulwafa

Published in: Gut Pathogens | Issue 1/2019

Abstract

Background

The colibactin and cytotoxic necrotizing factor 1 (Cnf 1) are toxins with cell cycle modulating effects that contribute to tumorgenesis and hyperproliferation. This study aimed to investigate the prevalence and pathologic effects of Cnf 1 and colibactin among hemolytic uropathogenic Escherichia coli (UPEC). The bioinformatics approach incorporated in this study aimed to expand the domain of the in vitro study and explore the prevalence of both toxins among other bacterial species. A total of 125 E. coli isolates were recovered from UTIs patients. The isolates were tested for their hemolytic activity, subjected to tissue culture and PCR assays to detect the phenotypic and genotypic features of both toxins. A rat ascending UTI in vivo model was conducted using isolates expressing or non-expressing Cnf 1 and colibactin (ClbA and ClbQ). The bioinformatics analyses were inferred by Maximum likelihood method and the evolutionary relatedness was deduced by MEGA X.

Results

Only 21 (16.8%) out of 125 isolates were hemolytic and 10 of these (47.62%) harbored the toxins encoding genes (cnf 1⁺, clbA⁺ and clbQ⁺). The phenotypic features of both toxins were exhibited by only 7 of the (cnf 1⁺clbA⁺clbQ⁺) harboring isolates. The severest infections, hyperplastic and genotoxic changes in kidneys and bladders were observed in rats infected with the cnf 1⁺clbA⁺clbQ⁺ isolates.

Conclusion

Only 33.3% of the hemolytic UPEC isolates exhibited the phenotypic and genotypic features of Cnf 1 and Colibactin. The in vivo animal model results gives an evidence of active Cnf 1 and Colibactin expression and indicates the risks associated with recurrent and chronic UTIs caused by UPEC. The bioinformatics analyses confirmed the predominance of colibactin pks island among Enterobacteriaceae family (92.86%), with the highest occurrence among Escherichia species (53.57%), followed by Klebsiella (28.57%), Citrobacter (7.14%), and Enterobacter species (3.57%). The Cnf 1 is predominant among Escherichia coli (94.05%) and sporadically found among Shigella species (1.08%), Salmonella enterica (0.54%), Yersinia pseudotuberculosis (1.08%), Photobacterium (1.08%), Moritella viscosa (0.54%), and Carnobacterium maltaromaticum (0.54%). A close relatedness was observed between the 54-kb pks island of Escherichia coli, the probiotic Escherichia coli Nissle 1917, Klebsiella aerogenes, Klebsiella pneumoniae and Citrobacter koseri.

Available only for authorised users

Nougayrède JP, Taieb F, De Rycke J, Oswald E. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Trends Microbiol. 2005;13:103–10. https://doi.org/10.1016/j.tim.2005.01.002.CrossRefPubMed

Dubois D, Delmas J, Cady A, Robin F, Sivignon A, Oswald E, et al. Cyclomodulins in urosepsis strains of Escherichia coli. J Clin Microbiol. 2010;48:2122–9. https://doi.org/10.1128/JCM.02365-09.CrossRefPubMedPubMedCentral

El-Aouar Filho RA, Nicolas A, De Paula Castro TL, Deplanche M, De Carvalho Azevedo VA, Goossens PL, et al. Heterogeneous family of cyclomodulins: smart weapons that allow bacteria to hijack the eukaryotic cell cycle and promote infections. Front Cell Infect Microbiol. 2017;7:208. https://doi.org/10.3389/fcimb.2017.00208.CrossRefPubMedPubMedCentral

Lax AJ. New genotoxin shows diversity of bacterial attack mechanisms. Trends Mol Med. 2007;13:91–3. https://doi.org/10.1016/j.molmed.2007.01.001.CrossRefPubMed

Brotherton, C. A. (2016). Investigations of the biosynthesis and structure of colibactin, a cytotoxin made by human-associated Escherichia coli.

Suresh A, Ranjan A, Jadhav S, Hussain A, Shaik S, Alam M, et al. Molecular genetic and functional analysis of pks-harboring, extra-intestinal pathogenic Escherichia coli from India. Front Microbiol. 2018;9:2631. https://doi.org/10.3389/fmicb.2018.02631.CrossRefPubMedPubMedCentral

Nougayrède JP, Homburg S, Taieb F, Boury M, Brzuszkiewicz E, Gottschalk G, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science. 2006;313:848–51. https://doi.org/10.1126/science.1127059.CrossRefPubMed

Faïs T, Delmas J, Barnich N, Bonnet R, Dalmasso G. Colibactin: more than a new bacterial toxin. Toxins. 2018;10(4):151. https://doi.org/10.3390/toxins10040151.CrossRefPubMedCentral

Abe CM, Salvador FA, Falsetti IN, Vieira MA, Blanco J, Blanco JE, et al. Uropathogenic Escherichia coli (UPEC) strains may carry virulence properties of diarrhoeagenic E. coli. FEMS Immunol Med Microbiol. 2008;52(3):397–406. https://doi.org/10.1111/j.1574-695x.2008.00388.x.CrossRefPubMed

10.

Ruiz J, Simon K, Horcajada JP, Velasco M, Barranco M, Roig G, et al. Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J Clin Microbiol. 2002;40:4445–9. https://doi.org/10.1128/JCM.40.12.4445-4449.2002.CrossRefPubMedPubMedCentral

11.

Krieger JN, Dobrindt U, Riley DE, Oswald E. Acute Escherichia coli prostatitis in previously health young men: bacterial virulence factors, antimicrobial resistance, and clinical outcomes. Urology. 2011;77:1420–5. https://doi.org/10.1016/j.urology.2010.12.059.CrossRefPubMed

12.

Raisch J, Buc E, Bonnet M, Sauvanet P, Darfeuille-Michaud A, Bonnet R. Colon cancer associated B2 Escherichia coli colonize gut mucosa and promote cell proliferation. World J Gastroenterol. 2014;20:6560. https://doi.org/10.3748/wjg.v20.i21.6560.CrossRefPubMedPubMedCentral

13.

Nowrouzian FL, Oswald E. Escherichia coli strains with the capacity for long-term persistence in the bowel microbiota carry the potentially genotoxic pks island. Microb Pathog. 2012;53(3–4):180–2. https://doi.org/10.1016/j.micpath.2012.05.011.CrossRefPubMed

14.

Payros D, Secher T, Boury M, Brehin C, Ménard S, Salvador-Cartier C, et al. Maternally acquired genotoxic Escherichia coli alters offspring’s intestinal homeostasis. Gut Microbes. 2014;5(3):313–512. https://doi.org/10.4161/gmic.28932.CrossRefPubMedPubMedCentral

15.

Johnson JR, Johnston B, Kuskowski MA, Nougayrede JP, Oswald E. Molecular epidemiology and phylogenetic distribution of the Escherichia coli pks genomic island. J Clin Microbiol. 2008;46:3906–11. https://doi.org/10.1128/JCM.00949-08.CrossRefPubMedPubMedCentral

16.

Martin P, Marcq I, Magistro G, Penary M, Garcie C, Payros D, et al. Interplay between siderophores and colibactin genotoxin biosynthetic pathways in Escherichia coli. PLoS Pathog. 2013;9:e1003437. https://doi.org/10.1371/journal.ppat.1003437.CrossRefPubMedPubMedCentral

17.

Feng Y, Mannion A, Madden CM, Swennes AG, Townes C, Byrd C, et al. Cytotoxic Escherichia coli strains encoding colibactin and cytotoxic necrotizing factor (CNF) colonize laboratory macaques. Gut Pathog. 2017;9:71. https://doi.org/10.1186/s13099-017-0220-y.CrossRefPubMedPubMedCentral

18.

Homburg S, Oswald E, Hacker J, Dobrindt U. Expression analysis of the colibactin gene cluster coding for a novel polyketide in Escherichia coli. FEMS Microbiol Lett. 2007;275:255–62. https://doi.org/10.1111/j.1574-6968.2007.00889.x.CrossRefPubMed

19.

Mousa JJ, Yang Y, Tomkovich S, Shima A, Newsome RC, Tripathi P, et al. MATE transport of the E. coli-derived genotoxin colibactin. Nat Microbiol. 2016;1:15009. https://doi.org/10.1038/nmicrobiol.2015.9.CrossRefPubMedPubMedCentral

20.

Falbo V, Pace T, Picci L, Pizzi E, Caprioli A. Isolation and nucleotide sequence of the gene encoding cytotoxic necrotizing factor 1 of Escherichia coli. Infect Immun. 1993;61:4909–14.PubMedPubMedCentral

21.

Blum G, Falbo V, Caprioli A, Hacker J. Gene clusters encoding the cytotoxic necrotizing factor type 1, Prs-fimbriae and alpha-hemolysin form the pathogenicity island II of the uropathogenic Escherichia coli strain J96. FEMS Microbiol Lett. 1995;126:189–95. https://doi.org/10.1111/j.1574-6968.1995.tb07415.x.CrossRefPubMed

22.

Caprioli A, Falbo V, Ruggeri FM, Baldassarri L, Bisicchia R, Ippolito G, et al. Cytotoxic necrotizing factor production by hemolytic strains of Escherichia coli causing extraintestinal infections. J Clin Microbiol. 1987;25:146–9.PubMedPubMedCentral

23.

Caprioli A, Donelli G, Falbo V, Possenti R, Roda LG, Roscetti G, et al. A cell division-active protein from E. coli. Biochem Biophys Res Commun. 1984;118:587–93.CrossRefPubMed

24.

Cavalieri SJ, Bohach GA, Snyder IS. Escherichia coli alpha-hemolysin: characteristics and probable role in pathogenicity. Microbiol Rev. 1984;48:326–43.PubMedPubMedCentral

25.

Cougnoux A, Dalmasso G, Martinez R, Buc E, Delmas J, Gibold L, et al. Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype. Gut. 2014;63:1932–42. https://doi.org/10.1136/gutjnl-2013-305257.CrossRefPubMed

26.

Dalmasso G, Cougnoux A, Delmas J, Darfeuille-Michaud A, Bonnet R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut Microbes. 2014;5:675–80. https://doi.org/10.4161/19490976.2014.969989.CrossRefPubMedPubMedCentral

27.

Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338:120–3. https://doi.org/10.1126/science.1224820.CrossRefPubMedPubMedCentral

28.

Alonso P, Blanco J, Blanco M, Gonzalez EA. Frequent production of toxins by Escherichia coli strains isolated from human urinary tract infections: relation with haemagglutination. FEMS Microbiol Lett. 1987;48:391–6.CrossRef

29.

Garcia A, Mannion A, Feng Y, Madden CM, Bakthavatchalu V, Shen Z, et al. Cytotoxic Escherichia coli strains encoding colibactin colonize laboratory mice. Microbes Infect. 2016;18:777–86. https://doi.org/10.1016/j.micinf.2016.07.005.CrossRefPubMedPubMedCentral

30.

Reppin F, Cochet S, El Nemer W, Fritz G, Schmidt G. High affinity binding of Escherichia coli cytotoxic necrotizing factor 1 (CNF1) to Lu/BCAM adhesion glycoprotein. Toxins. 2017;10:3. https://doi.org/10.3390/toxins10010003.CrossRefPubMedCentral

31.

Secher T, Samba-Louaka A, Oswald E, Nougayrède JP. Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells. PLoS ONE. 2013;8:e77157. https://doi.org/10.1371/journal.pone.0077157.CrossRefPubMedPubMedCentral

32.

Perry P, Wolff S. New Giemsa method for the differential staining 620 of sister chromatids. Nature. 1974;251:156.CrossRefPubMed

33.

Packeiser H, Lim C, Balagurunathan B, Wu J, Zhao H. An extremely simple and effective colony PCR procedure for bacteria, yeasts, and microalgae. Appl Biochem Biotechnol. 2013;169:695–700. https://doi.org/10.1007/s12010-012-0043-8.CrossRefPubMed

34.

Van Bost S, Jacquemin E, Oswald E, Mainil J. Multiplex PCRs for identification of necrotoxigenic Escherichia coli. J Clin Microbiol. 2003;41:4480–2. https://doi.org/10.1128/JCM.41.9.4480-4482.2003.CrossRefPubMedPubMedCentral

35.

Garcia TA, Ventura CL, Smith MA, Merrell DS. Cytotoxic necrotizing factor 1 and hemolysin from uropathogenic Escherichia coli elicit different host responses in the murine bladder. Infect Immun. 2013;81:99–109. https://doi.org/10.1128/IAI.00605-12.CrossRefPubMedPubMedCentral

36.

Mattsby-Baltzer I, Hanson L, Kaijser B, Larsson P, Olling S, Svanborg-Eden C. Experimental Escherichia coli ascending pyelonephritis in rats: changes in bacterial properties and the immune response to surface antigens. Infect Immun. 1982;35:639–46.PubMedPubMedCentral

37.

Larsson P, Kaijser B, Baltzer IM, Olling S. An experimental model for ascending acute pyelonephritis caused by Escherichia coli or proteus in rats. J Clin Pathol. 1980;33:408–12.CrossRefPubMedPubMedCentral

38.

Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution. 1985;39(4):783–91.CrossRefPubMed

39.

Jones DT, Taylor WR, Thornton JM. The rapid generation of mutation data matrices from protein sequences. Bioinformatics. 1992;8:275–82.CrossRef

40.

Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol Biol Evol. 2018;35:1547–9. https://doi.org/10.1093/molbev/msy096.CrossRefPubMedPubMedCentral

41.

Biemer JJ. Antimicrobial susceptibility testing by the Kirby–Bauer disc diffusion method. Ann Clin Lab Sci. 1973;3:135–40.PubMed

42.

Cavalieri SJ, Snyder IS. Effect of Escherichia coli alpha-hemolysin on human peripheral leukocyte viability in vitro. Infect Immun. 1982;36:455–61.PubMedPubMedCentral

43.

Mobley HL, Green DM, Trifillis AL, Johnson DE, Chippendale GR, Lockatell CV, et al. Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun. 1990;58:1281–9.PubMedPubMedCentral

44.

Landraud L, Gauthier M, Fosse T, Boquet P. Frequency of Escherichia coli strains producing the cytotoxic necrotizing factor (CNF1) in nosocomial urinary tract infections. Lett Appl Microbial. 2000;30(3):213–6. https://doi.org/10.1046/j.1472-765x.2000.00698.x.CrossRef

45.

Lu MC, Chen YT, Chiang MK, Wang YC, Hsiao PY, Huang YJ, et al. Colibactin contributes to the hypervirulence of pks + K1 CC23 Klebsiella pneumoniae in mouse meningitis infections. Front Cell Infect Microbiol. 2017;7:103. https://doi.org/10.3389/fcimb.2017.00103.CrossRefPubMedPubMedCentral

46.

Cuevas-Ramos G, Petit CR, Marcq I, Boury M, Oswald E, Nougayrede JP. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci. 2010;107:11537–42. https://doi.org/10.1073/pnas.1001261107.CrossRefPubMedPubMedCentral

47.

Island MD, Cui X, Warren JW. Effect of Escherichia coli cytotoxic necrotizing factor 1 on repair of human bladder cell monolayers in vitro. Infect Immun. 1999;67:3657–61.PubMedPubMedCentral

48.

Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PloS ONE. 2013;8(2):e56964. https://doi.org/10.1371/journal.pone.0056964.CrossRefPubMedPubMedCentral

49.

Horcajada JP, Soto S, Gajewski A, Smithson A, de Anta MTJ, Mensa J, et al. Quinolone-resistant uropathogenic Escherichia coli strains from phylogenetic group B2 have fewer virulence factors than their susceptible counterparts. J Clin Microbiol. 2005;43(6):2962–4. https://doi.org/10.1128/JCM.43.6.2962-2964.2005.CrossRefPubMedPubMedCentral

50.

Derakhshandeh A, Firouzi R, Motamedifar M, Arabshahi S, et al. Virulence characteristics and antibiotic resistance patterns among various phylogenetic groups of uropathogenic Escherichia coli isolates. Jpn J Infect Dis. 2015;68:428–31. https://doi.org/10.7883/yoken.JJID.2014.327.CrossRefPubMed

51.

Harwalkar A, Gupta S, Rao A, Srinivasa H. Lower prevalence of hlyD, papC and cnf-1 genes in ciprofloxacin-resistant uropathogenic Escherichia coli than their susceptible counterparts isolated from southern India. J Infect Public Health. 2014;7(5):413–9. https://doi.org/10.1016/j.jiph.2014.04.002.CrossRefPubMed

52.

Middendorf B, Hochhut B, Leipold K, Dobrindt U, Blum-Oehler G, Hacker J. Instability of pathogenicity islands in uropathogenic Escherichia coli 536. J Bacteriol. 2004;186(10):3086–96. https://doi.org/10.1128/JB.186.10.3086-3096.2004.CrossRefPubMedPubMedCentral

53.

Piatti G, Mannini A, Balistreri M, Schito AM. Virulence factors in urinary Escherichia coli strains: phylogenetic background and quinolone and fluoroquinolone resistance. J Clin Microbiol. 2008;46(2):480–7. https://doi.org/10.1128/JCM.01488-07.CrossRefPubMed

54.

Ahmed N, Dobrindt U, Hacker J, Hasnain SE. Genomic fluidity and pathogenic bacteria: applications in diagnostics, epidemiology and intervention. Nat Rev Microbiol. 2008;6(5):387. https://doi.org/10.1038/nrmicro1889.CrossRefPubMed

55.

López E, Elez M, Matic I, Blázquez J. Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli. Mol Microbiol. 2007;64(1):83–93. https://doi.org/10.1111/j.1365-2958.2007.05642.x.CrossRefPubMed

56.

Sonstein SA, Burnham JC. Effect of low concentrations of quinolone antibiotics on bacterial virulence mechanisms. Diagn Microbial Infect Dis. 1993;16(4):277–89. https://doi.org/10.1016/0732-8893(93)90078-L.CrossRef

Title: Prevalence and pathologic effects of colibactin and cytotoxic necrotizing factor-1 (Cnf 1) in Escherichia coli: experimental and bioinformatics analyses
Authors: Radwa N. Morgan
Sarra E. Saleh
Hala A. Farrag
Mohammad M. Aboulwafa
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Escherichia Coli
Published in: Gut Pathogens / Issue 1/2019
Electronic ISSN: 1757-4749
DOI: https://doi.org/10.1186/s13099-019-0304-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

NMR metabolomics reveals effects of Cryptosporidium infections on host cell metabolome

Two putative MmpL homologs contribute to antimicrobial resistance and nephropathy of enterohemorrhagic E. coli O157:H7

The influence of probiotic bacteria and human gut microorganisms causing opportunistic infections on Blastocystis ST3

Nonhemolysis of epidemic El Tor biotype strains of Vibrio cholerae is related to multiple functional deficiencies of hemolysin A

Prevalence of Helicobacter pylori infection and antibiotic resistance profile in Armenia

Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage